The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature clonal B cells. The aims of this study were to gain further insights into the nature of this activation and to assess its importance for the prolonged HC survival in this chronic disease. We show that HCs contain phosphorylated/activated p38 MAPK, JNK and ERK1/ERK2 (ERK1/2). PKC inhibitors increased the activation of p38 and JNK, but reduced the phosphorylation of ERK1/2. Moreover, PKC inhibition resulted in cell death; cell death was also observed when the activation of ERK1/2 in HCs was abrogated with an inhibitor of MEK1/2 activation. In addition to PKC, active Src kinase was also shown to be involved in the maintenance of Raf-independent ERK activation in HCs. During cell culture on a nonadherent surface, ERK phosphorylation was sustained, while phosphorylation of p38 and JNK decreased. This decrease was not observed in HCs cultured on vitronectin (VN), indicating that p38/ JNK activation is probably a consequence of in vivo HC interaction with VN present in abundance in the red pulp of the spleen. Taken together, these results suggest that active p38/JNK make HCs susceptible to apoptosis, but the cells are effectively rescued by ERK activation involving constitutively active PKC and Src. These findings are relevant for the understanding of the prolonged cell survival of HCs and their selective sensitivity to some chemotherapeutic agents.
Introduction
Hairy-cell leukemia (HCL) is unique among chronic Bcell leukemias in that the malignant cells show particularly pronounced features of activation . Thus, the cortical cytoskeleton of the malignant hairy cells (HCs) is clearly in a state of active reorganization as indicated by distinctive membrane ruffling and microvilli formation (Burthem and Cawley, 1996) . Other morphological features of metabolically highly active cells include a relative lack of chromatin condensation and abundant cytoplasm with plentiful mitochondria and ribosomes, together with scattered strands of rough endoplasmic reticulum (Burthem and Cawley, 1996) . The diagnostically important expression of tartrate-resistant acid phosphatase (Yam et al., 1971) is also an activation feature since normal lymphocytes express this isoenzyme only after stimulation (CaligarisCappio et al., 1985) . Lastly, the profile of surfaceantigen expression of HCs is that of highly activated cells (Pettitt et al., 1999) and includes high expression and constitutive activation of a number of adhesion receptors (Burthem et al., 1994) .
This activated state of HCs is not only reflected in the phenotype of the malignant cells, but also in their distinctive pattern of tissue invasion, in their prolonged survival and uniquely high sensitivity to interferon (aIFN) (Baker et al., 2002) , nucleosides (Piro et al., 1990) and some therapeutic monoclonal antibodies (Kreitman et al., 2001) .
Moreover, in order to have an effect on cell survival, the activation signals of HCs are likely, as in other normal and malignant cell types (Reuter et al., 1992) , to converge on activation of mitogen-activated protein kinase (MAPK) cascades (Davis, 1993; Cobb and Goldsmith, 1995; Marshall, 1995; Dent et al., 1998; Chang and Karin, 2001) . Given the central role of MAPKs in the pathogenesis and potential therapy of many malignancies, in the present study we have explored the state of activation of p38, JNK and ERK1/ERK2 (ERK1/2) (the principal members of the MAPK family) in HCs, and assessed their role in cell survival.
Results
In initial experiments, we have demonstrated a uniformly high level of protein phosphorylation in HCs, confirming the activated phenotype of these cells . Since the particularly prominent protein bands phosphorylated on both tyrosine and threonine were in the position of JNK and p38 MAPK, we initially focused on these two subfamilies of enzymes.
We then examined the state of ERK1/2 -MAPKs, which generally transmit signals for cell survival and thus oppose the potentially proapoptotic effects of activation of p38 MAPK and JNK (Xia et al., 1995; Birkenkamp et al., 1999) .
p38 and JNK are activated in circulating HCs
Peripheral blood (PB) HCs were resuspended in serumfree medium at 371C for 1-2 h on a nonadherent (poly [2-hydroxyethylmethacrylate] (Poly HEMA)-coated) surface in order to deprive the cells of stimuli induced by serum components and adhesion. The cells were then lysed, and the proteins in the lysates analysed by Western blotting with an antibody detecting the phosphorylated Thr-Gly-Tyr motif within activated p38 MAPK. This analysis showed that p38 is activated in HCs (Figure 1a ). In contrast, phospho-p38 MAPK was absent in normal PB B cells, but became detectable after 10 min cell incubation with TNFa ( Figure 1b ), a cytokine known to activate this kinase (Kyriakis and Avruch, 1996) . In CLL cells, phosphorylated p38 MAPK was either undetectable or present at only low levels ( Figure 1b ). Western blotting with isoformspecific antibodies showed strong expression of p38a in HCs, but complete absence of b and g isoforms and only traces of p38d (not shown). In vitro kinase assays of immunoprecipitated p38a confirmed that this isoform is active in HCs (Figure 1c) . Further Western blot analysis using phospho-specific MKK 3/6 antibodies showed that these upstream activators of p38 are also activated in HCs (Figure 1d ).
When similar analyses were carried out for JNK, variable phosphorylation of JNK1 and JNK2 was detected, together with phosphorylation of the upstream JNK activator MKK4 (Figure 2a, b) . In contrast to HCs, neither normal B cells nor CLL cells contained phosphorylated JNK. However, upon treatment of normal B cells with TNFa, JNK1, but not JNK2, did become phosphorylated (Figure 2c ). Activation of JNK in HCs was confirmed by in vitro kinase assay (Figure 2d ) and by the detection of phosphorylation of its substrate, c-Jun (Figure 2e ). In addition, cell lysates and nuclear extracts contained phosphorylated ATF-2 (Figure 2f ), the substrate of both JNK and p38 (Gupta et al., 1995) .
Altogether, these data show that, in contrast to normal B and CLL cells, HCs analysed directly ex vivo contain activated p38 MAPK and JNK1/JNK2.
ERK1 and ERK2 are also activated in HCs
When the lysates used above were analysed for activated ERK, Western blotting ( Figure 3a ) and in vitro kinase assays (not shown) demonstrated that ERK1/2 are also activated in HCs. In contrast, ERK1/2 were not phosphorylated in normal B cells, but became so after cell treatment with PMA ( Figure 3b ). In the CLL cells from three patients, ERK1/2 phosphorylation was absent in two cases and only weakly present in the third ( Figure 3b ). As in normal B cells, ERK1/2 became strongly phosphorylated in response to PMA (Figure 3c ).
The immediate upstream activators of ERKs are MEK1/2 (Marshall, 1994; Cobb and Goldsmith, 1995) . We therefore examined the phosphorylation state of these proteins in HCs. Figure 3d shows that MEK1/2 are constitutively phosphorylated/activated in these cells. Furthermore, in HCs, the phosphorylation of ERK was largely abrogated by PD98059 and by U0126 (Figure 3e ) both of which inhibit the activation of MEK1/2 (Alessi et al., 1995; Favata et al., 1998) .
Thus, both ERK1/2 and MEK1/2 are activated in HCs. In contrast, these MAPKs are not activated in normal PB B cells and only weakly in some CLL-cell clones.
PKC plays a role in the regulation of HC MAP kinases
We next considered involvement of PKC in the regulation of MAPKs in HCs. This seemed important because involvement of PKC in MAPK regulation is well established (Exton, 1994; Ping et al., 1999; Baines et al., 2002; Brandlin et al., 2002) . Also, it has been repeatedly demonstrated that other mature B cells acquire an HC-like phenotype after exposure to PKC Regulation of hairy-cell survival by MAPKs AS Kamiguti et al agonists such as PMA and bryostatin (Drexler et al., 1989; Southern et al., 1995) .
We first used Western blotting to establish the PKCisoform expression of HCs. As shown in Figure 4a , HCs were found consistently to express PKCa, b, d, e, m (band at 115 kDa) and z isoforms. When each of these isoforms was immunoprecipitated and tested by in vitro kinase assay, only PKCa was consistently found to be strongly active (Figure 4b ).
We next used inhibitors to explore how this PKCa contributes to the activation of p38, JNK and ERK MAPKs described above. We employed two inhibitors of PKC, namely Ro-32-0432 and safingol, because both reagents partially inhibited the PKCa activity of HCs (Figure 4b) .
Incubation of HCs with Ro-32-0432 increased p38 MAPK activity fourfold in the first 10 min of culture and also caused a less pronounced increase (1.3-fold) in the activity of JNK (Figure 4c ). These results were confirmed by the demonstration of increased activationrelated phosphorylation of both p38 and JNK in the presence of Ro-32-0432 (not shown).
We next examined the effect on ERK activation of Ro-32-0432 or safingol. In contrast to the observed upregulation of p38 and JNK activity, the activity of ERK1/2 was downregulated by these inhibitors (Figure 4d) .
In order to examine further the role of PKCa in the regulation of ERK, p38 and JNK, we used bryostatin 1 (Clarke et al., 2000) to downregulate this enzyme in HCs. After 24 h of culture in the absence of bryostatin 1, we observed preserved ERK phosphorylation in HCs, strong reduction in p38 phosphorylation and complete abrogation of JNK2, but not JNK1, phosphorylation (Figure 4e ). Culture with bryostatin 1 at concentrations varying between 10 and 100 nm over 24 h did not affect ERK phosphorylation, but caused concentration-dependent increase in phosphorylation of p38 MAPK without restoring JNK2 phosphorylation. The depletion of PKCa by bryostatin 1 was confirmed by Western blotting (not shown). This depletion had the same potentiating effect on p38 activation (and at high concentration also on JNK activation) as observed after cell treatment with the general PKC inhibitor Ro-32-0432. This suggests that the constitutively active PKC in HCs that suppresses p38 activation (and to a less extent that of JNK) is PKCa. However since, in contrast to Ro-32-0432, bryostatin 1 did not reduce ERK phos- Taken together, these data indicate that, in HCs, active PKCs have both positive and negative regulatory effects on MAPKs, upregulating the activity of ERKs and downregulating that of p38 and JNK.
Active MAPKs are involved in the regulation of HC survival
It has been proposed that the balance between ERK and JNK/p38 MAPK plays an important role in cell survival (Xia et al., 1995; Johnson et al., 1996; Birkenkamp et al., 1999; Nagata and Todokoro, 1999) . Since we showed above that these enzymes are already active in HCs, we next explored how this balance affects the survival of HCs in culture.
Under our culture conditions, the viability of nonadherent cells in serum-free medium was maintained at >70% over a period of 6 days. However, when the cells were treated with the MEK1/2 inhibitor PD98059, their survival was markedly decreased (Figure 5a ). Since as expected, MEK1/2 inhibition blocked ERK1/2 activation in HCs (Figure 3e ), this suggests that active ERK provides a survival signal for HCs. As our data also show that PKC inhibitors decrease ERK activation (Figure 4d ), the survival of HCs treated with Ro-32-0432 was analysed next. This PKC inhibitor also shortened HC survival ( Figure 5c ). Similar results were obtained using safingol (10 mm) and other PKC inhibitors (Go¨6976, 10 mm; Gö 6850, 10 mm and calphostinc, 200 nm) (not shown).
Since we show above that PKC inhibition increases p38 MAPK and JNK activity, but at the same time reduces ERK activation (Figure 4 ), these data support the notion that HC survival is, at least in part, determined by the balance between the potential proapoptotic effects of p38/JNK and the antiapoptotic ones of ERK. To test this notion, we used the p38 MAPK-specific inhibitor SB202190, either alone or in combination with the PKC inhibitor Ro-32-0432. Alone, SB202190 had no effect on in vitro-HC survival ( Figure 5b ). However, treatment of HCs with a combination of SB202190 and Ro-32-0432 clearly protected cells from the accelerated death observed in Figure 5c ). These results indicate that active PKC rescues HCs from apoptosis through both activation of ERK and suppression of p38 MAPK activity. In addition to strongly expressed p38a, the only other isoform found in HCs was the weakly expressed p38d. Since SB202190 at the concentration employed very effectively inhibits p38a, but not p38d (Jiang et al., 1997) , this suggests that p38a is the principal isoform involved in the regulation of HC survival described here.
As 2-chlorodeoxyadenosine (CdA) is one of the major therapeutic agents used in HCL (Piro et al., 1990; Bastie et al., 1999; Savoie and Johnston, 2001 ), we investigated whether CdA killing of HCs can be enhanced by MEK1/ 2 inhibitors. Such a synergistic effect of MEK inhibitors and another therapeutic nucleoside analogue (araC, 1-bd-arabinofuranosylcytosine) has previously been reported on studies with myeloid leukemia cells (Milella et al., 2001) . In experiments with cells from three HCL patients, CdA (1 mm) alone progressively reduced the number of viable cells to 28.972.3% (mean7s.d.) at day 5. The number of surviving cells was further reduced to 4.972.0% in the presence of 10 mm U0126 and to 13.771.0% with 50 mm PD98059 (Po0.05 for both inhibitors). This clearly shows that combined treatment of HCs with both CdA and MEK1/2 inhibitors has a more profound effect on HC survival than has CdA alone.
Phosphorylation of JNK/p38 MAPK, but not that of ERK1/2, progressively diminishes during cell culture
The signals observed in malignant cells arise partly from oncogenic transformation and partly from environmental stimulation. In order to establish which of the signals identified above in HCs are inherited from in vivo stimulation and which are truly constitutive and therefore of intrinsic origin, we next explored how deprivation of external signals, including those from serum and cell adhesion, affects the persistence of MAPK activation in HCs. We observed that while ERK1/2 phosphorylation remained unchanged, that of p38 MAPK and JNK progressively diminished over 5 days of culture (Figure 6a ) whether or not serum was present in the culture medium (Figure 6b ). Thus, ERK activation in HCs appears to be truly constitutive, while activation of p38 MAPK and JNK is dependent on external stimulation.
Given the importance of the balance between the effects of ERK and p38/JNK for cell survival, our We next attempted to understand the mechanism(s) involved, first in the progressive loss of p38/JNK and, second, in the persistent activation of ERK in cultured HCs.
Loss of p38/JNK activation can be restored by cell adhesion
The decrease in p38/JNK phosphorylations during cell culture raised the question of the origin of the stimulus for their activation observed when the HCs were tested directly ex vivo. In our culture experiments, we employed polyHEMA-coated surfaces to avoid possible signalling originating from cell adhesion (HCs are adhesive cells and have activated adhesion receptors; Burthem et al., 1994) . Since adhesion is known to generate signals for p38 activation (Chen et al., 2001) , it seemed reasonable to postulate that adhesion might provide the stimulus for persistent activation of these enzymes. To test this hypothesis, we cultured HCs on vitronectin (VN)-coated plastic. This adhesive ligand was chosen because VN is a prominent component of the extracellular matrix (ECM) of the splenic red pulp (Simonsen et al., 1985) for which HCs have a particular predilection (Burthem and Cawley, 1996) . Also, it is known that HCs possess VN receptors and strongly interact with this ECM component (Burthem et al., 1994) . Figure 7a shows that, in contrast to the loss of phosphorylation of JNK and p38 in HCs on poly-HEMA (Figure 6 ), these phosphorylations remained Figure 6 The activation of ERK1/ERK2 in HCs is sustained ex vivo, but that of p38 MAPK and JNK is not. (a) HCs (10 7 cells/ml) were cultured for up to 5 days on a nonadherent polyHEMAcoated surface in a serum-free medium. Cell lysates were prepared, and the phosphorylation state of kinases examined by Western blotting with relevant antibodies as described in the legends of previous figures. The bottom panel shows immunoblots of b-actin as loading controls. (b) To examine whether the rapid waning of p38 MAPK phosphorylation can be prevented by the presence of serum, HCs were cultured for 24 h in the presence or absence of FCS -the presence of serum did not affect the rapid loss of p38 phosphorylation. The data in both (a) and (b) are representative of three independent experiments with cells from three different patients Figure 7 Cell adhesion to VN prevents the in vitro decline of p38/ JNK phosphorylation in HCs and potentiates cell killing by MEK1/2 inhibitors. To examine whether adhesion can prevent the rapid ex vivo decrease in p38 MAPK and JNK phosphorylation/ activation (Figure 6 ), HCs (10 7 cells/ml) were cultured on wells precoated with 20 mg/ml VN (for 24 h at 41C). (a) HCs were cultured for up to 2 days and the state of p38/JNK phosphorylation examined as in previous figures at days 0, 1 and 2. The figure shows representative results of three experiments involving three different HCL patients. (b) Untreated HCs or cells treated daily with U0126 (10 mm) were cultured for up to 4 days on either polyHEMA-or VN-coated tissue culture plastic. Similar results were obtained with 50 mm PD98059. Results are means of duplicate determinations in one case and were reproduced in a second experiment with cells from a different patient (not shown). Cell viability was measured by dual staining with ethidium bromide and acridine orange as described in Materials and methods
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AS Kamiguti et al constant in cells cultured on VN. This shows that adhesion via a v integrin(s) provides a stimulus for activation of these MAPKs. It therefore seems possible that the p38/JNK phosphorylations observed in HCs tested directly ex vivo originates from recent stimulation in vivo by adhesive ligands. To examine whether the potentially proapoptotic effects of this p38/JNK activation through adhesion are counterbalanced by constitutively active ERK, we next examined the effect of MEK1/2 inhibitors on the survival of HCs cultured on VN or polyHEMA. Figure 7b shows that, in the absence of the MEK1/2 inhibitor U0126, HC survival on polyHEMA and VN was comparable. However, in the presence of 10 mm U0126 or 50 mm PD98059 (not shown), the survival of cells on VN was shorter than that of nonadherent HCs on polyHEMA ( Figure 5 ). These observations indicate that, when constitutively active ERK is inhibited, HCs on VN undergo more readily apoptosis presumably because the MAPK signalling balance is tipped in favor of apoptosis as a result of sustained activation of p38/ JNK on this adhesive protein.
Mechanism of the constitutive activation of ERK in HCs
In order to examine whether the constitutive MEK1/2-ERK1/2 activation described earlier involves the classical Ras-Raf pathway, we first measured the expression and state of activation of the different Raf isoforms in HCs, using CLL cells for comparison. Figure 8a shows that B-Raf (the 90 kDa form) is the most strongly and uniformly expressed isoform in both HCs and CLL cells. c-Raf was also found to be strongly expressed, while ARaf expression was comparatively weak except in one case of CLL. We next measured the state of activation of these Raf isoforms by in vitro kinase assay (Figure 8b ). With the exception of one case of HCL, all other tested cells showed weak constitutive activity of B-Raf. In contrast, little or no constitutive activity of either c-Raf or A-Raf could be detected in HCs. Confirmation that cRaf is not activated in HCs was obtained by demonstration that this kinase is not phosphorylated on the Ser338 known to be an important site for the full activation of c-Raf (Mason et al., 1999) (Figure 8c ). However, when HCs were incubated with PMA+calcium ionophore for 10 min, clear activation of c-Raf was observed ( Figure  8c, d) .
Since Raf expression and activation were found to be very similar in both HCs and CLL cells and since HCs show pronounced ERK phosphorylation/activation while CLL cells do not, it is unlikely that the RasRaf pathway is responsible for the strong constitutive ERK phosphorylation consistently observed in HCs. Furthermore, treatment of HCs with sulindac sulfide, an agent known to inhibit the interaction of Ras with Raf (Herrmann et al., 1998) , had no effect on ERK Regulation of hairy-cell survival by MAPKs AS Kamiguti et al phosphorylation (not shown). ZM336372, an inhibitor of Raf kinase activity (Hall-Jackson et al., 1999) , also had no effect. Taken together, these data indicate that the constitutive activation of MEK1/2 and ERK in HCs is largely or totally independent of Raf.
As a result of the reported high levels of expression and activity of Src and Src-related kinases in HCs (Linch et al., 1993) , we next explored whether these enzymes play an upstream role in the activation of ERK. We therefore treated HCs with PP1, a potent inhibitor of Src-family kinases; such treatment substantially inhibited the activities/phosphorylation of both MEK and ERK (Figure 9a ). These data suggest that Src-family kinases also play a role in the persistent constitutive ERK activation observed in HCs.
The PP1 inhibitor is more specific for p60 Src than for other Src-family kinases (Carlomagno et al., 2002) . We therefore used a phospho-specific antibody recognizing Tyr416 of p60
Src to examine the activation state of this kinase in HCs. Figure 9b shows that p60 Src is constitutively and persistently activated/phosphorylated in HCs.
Taken together with our data concerning the role of PKC in MAPK activation (Figure 4) , these results indicate that the upstream signalling components involved in ERK activation include both constitutively active Src and PKC.
Discussion
It has been recognized for some time that HCs are strongly constitutively activated cells (Burthem and Cawley, 1996) . However, biochemical data concerning the nature of this activation are few . We now demonstrate for the first time that HCs show pronounced activation of p38 MAPK, JNK and ERK1/2 not observed in normal B and CLL cells. The activation state of p38 and JNK was substantiated by the presence, in HCs, of phosphorylated substrates of these kinases, ATF-2 and c-Jun. The activation of all these kinases was shown to involve regulation by active PKC. ERK activation was also dependent on active Src. Although p38 MAPK and JNK can generate potential proapoptotic signals (Xia et al., 1995) , HCs clearly have a survival mechanism, which, according to the present study, includes constitutively activated ERKs.
We found that the majority of HCs retain their viability for several days when cultured in the absence of stimuli produced by cell adhesion and serum factors. During this culture, ERK activation was sustained, while the activities of both p38 MAPK and JNK progressively diminished. ERK activation was clearly dependent on MEK1/2 since the inhibition of MEK1/2 activation by PD98059 and U0126 resulted in decreased ERK the phosphorylation. This inhibition of MEK1/2 also resulted in pronounced acceleration of cell death, showing the importance of ERK activation for HC survival. These results are in agreement with reported work showing that in other cell types inhibition of ERK promotes apoptosis (Nagata and Todokoro, 1999) .
The best recognized pathway leading to ERK activation involves Ras-Raf-MEK-ERK (Marshall, 1994; Cobb and Goldsmith, 1995) . However, our results indicate that, in HCs, MEK activation is unlikely to involve Ras and Raf, but does involve PKC and Src.
HCs expressed all three isoforms of Raf at levels comparable to those found in CLL cells. However, neither c-nor A-Raf was active and only low levels of BRaf were detected in two of three cases of HCL studied. Moreover, similar low levels of active B-Raf were observed in CLL cells that did not contain active ERK, but this MAPK was highly activated in the HCL case in which the cells did not contain active B-Raf. These observations, together with the failure of inhibition of the Ras-Raf pathway to affect ERK activation, strongly suggest that ERK activation in HCs occurs independently of Ras and Raf. The noninvolvement of the Ras-Raf pathway was further confirmed by the absence of the c-Raf phosphorylation at the Ser338 known to be important for full activation of this kinase (Mason et al., 1999) . However, full Raf activation in HCs was achieved through exogenous stimulation with phorbol esters. In contrast to the failure of Ras-Raf inhibitors to affect ERK phosphorylation in HCs, PKC inhibitors abrogated activation of this MAPK and shortened cell survival. PKC can also activate this pathway through generation of Ras-GTP/Raf complexes (Marais et al., 1998) and through activation of Raf itself (Kolch et al., 1993; Cai et al., 1997) . However, PKC can stimulate ERK through other pathways involving direct and indirect activation of MEK (Avdi et al., 1996; Corbit et al., 1999; Ping et al., 1999; Karandikar et al., 2000) . Our results indicate that the latter is the case in HCs, because in our studies Raf was not involved in MEK-ERK activation in these cells. Such Ras/Raf-independent activation of MEK-ERK is known to occur in other cell types stimulated with different stimuli (Hindley and Kolch, 2002; Nadal-Wollbold et al., 2002) .
In addition to positive regulation of ERK, PKC has been shown in neurons to negatively regulate the activity of p38 MAPK in parallel with prevention of apoptosis (Behrens et al., 1999; Zhang et al., 1999) . Our data show that blockade of the constitutively active PKC in HCs not only reduces the phosphorylation of ERKs, but also results in an increase in p38 MAPK activation in parallel with decreased cell survival in culture. This shortening of cell survival is likely to be due to both ERK inhibition and increased p38 MAPK activity since the inhibition of the latter kinase prevented the cell death caused by PKC(s) inhibition. Thus, the negative regulation of p38 MAPK activity and positive regulation of ERKs in HCs by constitutively active PKC(s) are likely to play a key role in the clear cytoprotective effect of the latter enzyme. Moreover, the results of our study are in full agreement with the proposal that cell survival is influenced by the balance between the activations of ERKs and p38/JNK MAPKs Ichijo, 1999; Nagata and Todokoro, 1999) .
The presence in HCs of constitutively active PKC has been suspected for some time (Genot et al., 1993) , but the present study constitutes the first demonstration of the likely central role of an active PKC in HC biology. Regarding specific PKC isoforms, we found that HCs express PKCa, b, d, e, m and z isoforms. In vitro kinase assays demonstrated that only PKCa is strongly and consistently activated in HCs. As regards PKCb, although this enzyme was strongly expressed in Western blots, attempts to immunoprecipitate it for in vitro kinase assay were not successful. However, our preliminary confocal studies have shown that PKCb in HCs is largely translocated to the plasma membrane, indicating that this isoenzyme is also probably activated in these cells. Other expressed PKC isoforms were either inactive or showed only low activity in some HCL cases.
In an attempt to define the role of PKCa relative to other PKC isoforms in the regulation of ERK, p38 and JNK, we downregulated PKCa with bryostatin 1 and compared the effects of this agent with those of the general PKC inhibitor Ro-32-0432. Treatment of HCs with either agent caused similar increases in p38 activation but, in contrast to Ro-32-0432, bryostatin 1 had no effect on ERK activity. We therefore conclude that PKC-dependent suppression of p38 is mediated by PKCa, while ERK activation involves other isoform(s).
Our demonstration here that p38/JNK phosphorylations progressively decline when HCs are deprived of microenvironmental stimulation suggests that these phosphorylations in HCs tested directly ex vivo result from in vivo stimulation. Moreover, when the HCs were cultured on VN, the phosphorylation of both MAPKs remained unchanged during culture. HCs express both a v b 3 and a v b 1 integrins (Burthem et al., 1994) and home to the VN-rich red pulp of the spleen (Burthem and Cawley, 1996) . Others have also demonstrated that a v expressed on invasive cancer cells generates signals leading to p38 phosphorylation (Chen et al., 2001) . We therefore suggest that circulating HCs have received signals for p38/JNK activation during their passage through spleen. This p38/JNK activation itself does not result in the induction of apoptosis, and our present and previous studies (Baker et al., 2002) suggest that this is because of the cytoprotective effect of ERK activated by PKC and possibly of other cosignals such as those that activate NFkB (Busuttil et al., 2002) . This conclusion is supported by our demonstration that the cell death induced by MEK inhibition is accelerated when cells are cultured on VN to restore activation of p38. Also, the role of ERK in cytoprotection of HCs is further emphasized by our findings that MEK inhibition potentiated the apoptotic effect of CdA, a nucleoside used for the therapy of HCL (Piro et al., 1990; Bastie et al., 1999; Savoie and Johnston, 2001) . Moreover, constitutive activation of p38 MAPK may contribute to the pronounced sensitivity of HCs to aIFN, because in other cells activation of this MAPK is required for STAT1 phosphorylation and transcriptional activation induced by interferon (Goh et al., 1999) .
Regarding the origin of the PKC and MAPK activations demonstrated here, these activations must be directly or indirectly related to an as yet unknown oncogenic event(s). The present studies exclude mutations of the MAPKs themselves as a cause of their constitutive activation. Therefore, further studies of upstream activation signals are required in order to identify their origin. Such studies will need to account for the dependence of MAPK activation on both Src and PKC. In addition, it will be necessary to differentiate between signals induced by autocrine cytokines already known to be produced by HCs (Cordingley et al., 1988; Chen et al., 1999; Gruber et al., 1999; Harris et al., 2000 ; Aziz KA, Till KJ, Chen HJ, Slupsky JR, Cawley JC and Zuzel M, submitted) and those attributable to primary transformation of signalling component(s).
In conclusion, the present work provides a basis for further studies aimed at identifying the causative factors involved in the malignant transformation of HCs. Also, our findings are of clear relevance for present and future therapies of HCL involving the inhibition of pathogenetically important signals. Since many oncogenic signals converge on MAPK pathways (McCubrey et al., 2000) , the fate of many malignant-cell types is likely to depend on the relative states of activation of the different MAPKs. The present work, therefore, has a general interest extending beyond the pathogenesis and potential therapy of HCL.
Materials and methods

Reagents
Propidium iodide (PI), 3,3 0 -dihexolyloxacarbocyanine iodide (DiOC 6 ), polyHEMA, phenylmethanesufonyl fluoride (PMSF), molecular weight markers, leupeptin, myelin basic protein, phorbol 12-myristate 13-acetate (PMA), CdA and ATP were purchased from Sigma-Aldrich (Dorset, UK). Recombinant human TNFa was purchased from R&D Systems (Oxon, UK). Recombinant GST-(K97M) MEK (kinase-dead) was a generous gift from Dr UR Rapp (University of Wu¨rzburg, Germany). Tissue culture media and Lymphoprep were from Gibco (Paisley, UK); fetal calf serum (FCS) was purchased from Labtech International Ltd. (East Sussex, UK). The MiniMACs magnetic cell purification system was purchased from Miltenyi Biotec (Bisley, UK). PKC and MAPK inhibitors were from Calbiochem-Novabiochem (Nottingham, UK); aprotinin was obtained from Bayer (Newbury, UK). The Src-family kinase inhibitor PP1 (4-amino-5-[4-methylphenyl]-7-[t-butyl]pyrazolo[3,4-d]pyrimidine) and bryostatin 1 were purchased from Alexis Corporation (Nottingham, UK). Protein G-Sepharose was purchased from Zymed (San Francisco, CA, USA). PVDF (Immobilon-P) membrane from Millipore (Bedford, MA, USA), enhanced chemiluminescence (ECL) reagent, [g-32 P]ATP (3000 Ci/mmol) and Hyperfilmt from Amersham Pharmacia Inc. (Buckinghamshire, UK) were also used. Purified VN was prepared from human serum as described before (Burthem et al., 1994) . All other reagents used were of analytical grade.
Patients and cell isolation
HCs were obtained with informed consent from PB of patients with typical HCL as determined by clinical presentation, morphology, tartrate-resistant-acid-phosphatase staining and immunophenotype. Normal B and CLL cells were obtained from PB of healthy volunteers and of chronic lymphocytic leukemia patients upon informed consent from. Cells were isolated from PB by density-gradient centrifugation on Lymphoprep. B-cell purity was increased to >95% by removing T lymphocytes and monocytes with magnetic beads coated with CD3 and CD14 using the MiniMACs magnetic cell purification system. Unless stated otherwise, cells were washed in RPMI 1640 and resuspended at 10 7 cells/ml in either RPMI or QBSF-51 with either 1 mg/ml bovine serum albumin (BSA) or 10% FCS and then left undisturbed for 60 min in a CO 2 incubator at 371C prior to use.
Cell survival
Untreated or treated cells were cultured in 24-well tissue culture plates coated with polyHEMA to avoid cell adhesion. Cell survival was measured by FACS analysis of cells stained with a combination of 5 mg/ml PI and 40 nM DiOC 6 . Dead cells are PI permeable and lose their mitochondrial potential required for DiOC 6 , staining and are therefore PI bright, DiOC 6 dim. Cell survival was also measured by dual staining of the cells with ethidium bromide and acridine orange as described before (Baker et al., 2002) .
Preparation of cell lysates and nuclear extracts
Cells pelleted by centrifugation at 13 000 g for 1 min were lysed in radioimmunoprecipitation assay (RIPA) buffer (158 mm NaCl, 1 mm EGTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, in 10 mm Tris-HCl pH 7.2, containing 1 mm sodium orthovanadate, 1 mm PMSF, 1 mg/ml leupeptin and 100 U/ml aprotinin) for 1 h at 41C. Alternatively, pellets were lysed in SDS sample buffer (62.5 mm Tris-HCl pH 6.8, 0.2% SDS, 10% glycerol, 50 mm dithiothreitol, 0.1% bromophenol blue) followed by 15 s sonication and 3 min boiling. Nuclear extracts were prepared according to the method of Dignam et al. (1983) .
Antibodies
Antibodies to phosphotyrosine (PY20), to PKC isoforms, to mouse and rabbit IgG conjugated to HRP were obtained from Transduction Laboratories (Lexington, KY, USA). Polyclonal rabbit antibodies against phosphorylated p38 MAPK, JNK, MKK3/6, MKK4, c-Jun, MEK1/2 and p60 Src were obtained from New England Biolabs (Beverly, MA, USA). Rat anti-Raf-1 phospho-Ser338 was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Monoclonal antibodies (mAb) against human phosphorylated ATF-2 and ERK1/2 and polyclonal antibodies against nonphosphorylated p60
Src , JNK1, p38a MAPK, p38b MAPK, p38d MAPK (SAPK4), p38g MAPK (ERK6), ATF-2, ERK, MEK1/2, MKK3, MKK4 and c-Jun were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). c-Raf mAb and antibodies against recombinant A-Raf and B-Raf were purchased from Santa Cruz. mAb 12S and antibody against recombinant c-Raf were kindly provided by Dr UR Rapp (University of Wiirzburg, Germany). The mAb against b actin was from Sigma.
Immunoprecipitation
Cell extracts were precleared for 1 h with protein G-Sepharose. Antibody (1-5 mg/ml) was then added, and mixtures incubated with agitation overnight at 41C. The immunocomplexes were subsequently precipitated on protein G-Sepharose for another 1 h at 41C. Beads were washed four times in RIPA buffer. Controls containing precipitated antibody only were prepared in the same manner.
Western blotting
Cell extracts were mixed with equal volumes of 2 Â sample buffer, and proteins analysed by SDS-PAGE, followed by Western blotting. Blocked membranes (with either 5% BSA or low-fat milk in 50 mm Tris-HCl pH 7.5 containing 150 mm NaCl and 0.1% Tween 20 for 1 h at 371C) were incubated with appropriate primary antibody, washed, and then incubated with a secondary HRP-labelled antibody. After washing, protein blots were developed with ECL reagent and then immediately exposed to film. Some immunoblots were also analysed by scanning densitometry. Where necessary, blots were stripped for 30 min at 601C using 62.5 mm Tris-HCl pH 6.7 containing 2% SDS and 100 mm 2-mercaptoethanol. Membranes were then washed twice, blocked and reprobed as above.
In vitro kinase assay
Precleared cell extracts were prepared as for immunoprecipitation and washed in RIPA buffer. Beads with bound immunoprecipitated proteins were further washed once in 50 mm HEPES pH 7.6 and then in 10 mm HEPES pH 7.6 (kinase assay buffer), both containing 10 mm MgCl 2 . Then, 30 ml of kinase assay buffer containing 1 mm ATP, 500 mg/ml substrate (myelin basic protein or GST-(K97M) MEK), 200 mm sodium orthovanadate and 100 mCi/ml [g-32 P]ATP was added to the immunoprecipitates for 30 min at room temperature. The reaction was terminated by the addition of 50 ml SDS sample buffer and the sample heated at 951C for 5 min. The mixture was resolved on SDS-PAGE in 12% gels as above. Proteins were transferred to nylon membranes as above and these were autoradiographed with the aid of an intensifying screen. Kinases contained in the immunoprecipitates were analysed by Western blotting with specific antibodies.
